Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 25 min ago
Peer-reviewedCC BY 4.0Frontiers in Cardiovascular Medicine

Colchicine use and clinical outcomes in acute myocarditis: a retrospective cohort study

  • Sukruth Pradeep Kundur1
  • Matthew Sadler1,2
  • Aamir Shamsi1,2
  • Cristina Madaudo1,3
  • William Chick1,2
  • Daniela Noakes1,2
  • Mattia Manzoni4
  • Beatrice Perkan4
  • Paul A. Scott1,2
  • Antonio Cannatà1,2,5
  • Daniel I. Bromage1,2
5 affiliations
  1. 1School of Cardiovascular Medicine and Sciences, King’s College London British Heart Foundation Centre of Excellence
  2. 2King’s College Hospital NHS Foundation Trust
  3. 3Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo
  4. 4Università Degli Studi di Milano
  5. 5KHP Centre for Translational Medicine
Read full textPDFDOICite

Abstract

Background: Acute myocarditis (AM) is an inflammatory disease of the myocardium associated with ventricular dysfunction, arrhythmia, and progression to cardiomyopathy. Current management remains supportive, and no targeted anti-inflammatory therapy has demonstrated proven benefit on cardiovascular outcomes outside specific histological subtypes. Colchicine is an inexpensive, widely available anti-inflammatory agent with an established role in pericarditis, yet real-world data on its association with clinical outcomes in confirmed AM remain limited.

Methods: Patients with cardiac magnetic resonance-confirmed AM were retrospectively included. The primary outcome was echocardiographic maintenance or recovery of LVEF to a follow-up of ≥50%. Secondary outcomes were all-cause mortality, absolute change in LVEF, and an absolute LVEF improvement of ≥10%.

Results: A total of 243 patients with AM were included in the study, with 63 receiving colchicine and 178 not. Colchicine-treated patients were significantly younger (median 29 vs. 39 years; p < 0.001) with a similar sex distribution, although clinical presentation differed between groups. Follow-up LVEF of ≥50%, evaluable in 93 patients, was more frequent in colchicine-treated patients (95% vs. 70%; p = 0.035) and persisted after adjustment for age and sex (OR 5.10, 95% CI 1.14–48.7; p = 0.03), with directionally consistent results in a propensity score-matched sensitivity analysis. All-cause mortality occurred in 1 of 63 colchicine-treated patients (1.6%) and 12 of 178 untreated patients (6.7%), with no significant difference after age and sex adjustment (OR 0.58, 95% CI 0.06–2.76; p = 0.53). Absolute change in LVEF and improvement ≥ 10% did not differ significantly between groups.

Conclusions: Colchicine use was associated with more frequent maintenance or recovery of left ventricular function, although these findings are exploratory in the context of the limitations of this study. Further prospective evidence will highlight the efficacy and scope of colchicine in patients with AM.

Related

  1. Endomyocardial Biopsy and Clinical Outcomes in Acute Myocarditis ― Multicenter Cohort Study ―
    Junho Hyun, Kyung-Hee Kim, Minjung Bak +5
    Circulation JournalPeer-reviewedCC BY-NC-NDFull textCardiovascular medicineJ-STAGE
  2. Thrombophilic Variants and Clinical Outcomes in Young Ischaemic Stroke Patients Undergoing Mechanical Thrombectomy: A Retrospective Cohort Study
    Ebru Marzioglu Ozdemir, Gokhan Ozdemir
    Journal of cardiovascular development and diseasePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  3. Clinical outcomes of concurrent repair of occult contralateral inguinal hernias during TAPP: a retrospective cohort study
    Hanxia Hao, Lijia Liu, Yao Wang +2
    Frontiers in surgeryPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  4. Clinical Performance and Survival Outcomes of All-on-4 Full-Arch Implant-Supported Prostheses in Patients With a Completely Edentulous Arch: A Retrospective Cohort Study
    Jay Gohil, Mohammed Taslim Fathima, Dilip Chakravarthy +3
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Clinical characteristics, long-term outcomes, and prognostic factors in linear IgA bullous dermatosis: A retrospective cohort study across the age spectrum in China, 2008-2025.
    Zhe Wang, Zhenzhen Wang, Wenchao Li +9
    JAAD internationalPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{kundur2026colchicine,
  title = {{Colchicine use and clinical outcomes in acute myocarditis: a retrospective cohort study}},
  author = {Sukruth Pradeep Kundur and Matthew Sadler and Aamir Shamsi and Cristina Madaudo and William Chick and Daniela Noakes and Mattia Manzoni and Beatrice Perkan and Paul A. Scott and Antonio Cannatà and Daniel I. Bromage},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  month = oct,
  doi = {10.3389/fcvm.2026.1930042},
  url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1930042/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Colchicine use and clinical outcomes in acute myocarditis: a retrospective cohort study
AU  - Sukruth Pradeep Kundur
AU  - Matthew Sadler
AU  - Aamir Shamsi
AU  - Cristina Madaudo
AU  - William Chick
AU  - Daniela Noakes
AU  - Mattia Manzoni
AU  - Beatrice Perkan
AU  - Paul A. Scott
AU  - Antonio Cannatà
AU  - Daniel I. Bromage
PY  - 2026
DA  - 2026/10/14
JO  - Frontiers in Cardiovascular Medicine
DO  - 10.3389/fcvm.2026.1930042
UR  - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1930042/full
AB  - Background: Acute myocarditis (AM) is an inflammatory disease of the myocardium associated with ventricular dysfunction, arrhythmia, and progression to cardiomyopathy. Current management remains supportive, and no targeted anti-inflammatory therapy has demonstrated proven benefit on cardiovascular outcomes outside specific histological subtypes. Colchicine is an inexpensive, widely available anti-inflammatory agent with an established role in pericarditis, yet real-world data on its association with clinical outcomes in confirmed AM remain limited.  Methods: Patients with cardiac magnetic resonance-confirmed AM were retrospectively included. The primary outcome was echocardiographic maintenance or recovery of LVEF to a follow-up of ≥50%. Secondary outcomes were all-cause mortality, absolute change in LVEF, and an absolute LVEF improvement of ≥10%.  Results: A total of 243 patients with AM were included in the study, with 63 receiving colchicine and 178 not. Colchicine-treated patients were significantly younger (median 29 vs. 39 years; p < 0.001) with a similar sex distribution, although clinical presentation differed between groups. Follow-up LVEF of ≥50%, evaluable in 93 patients, was more frequent in colchicine-treated patients (95% vs. 70%; p = 0.035) and persisted after adjustment for age and sex (OR 5.10, 95% CI 1.14–48.7; p = 0.03), with directionally consistent results in a propensity score-matched sensitivity analysis. All-cause mortality occurred in 1 of 63 colchicine-treated patients (1.6%) and 12 of 178 untreated patients (6.7%), with no significant difference after age and sex adjustment (OR 0.58, 95% CI 0.06–2.76; p = 0.53). Absolute change in LVEF and improvement ≥ 10% did not differ significantly between groups.  Conclusions: Colchicine use was associated with more frequent maintenance or recovery of left ventricular function, although these findings are exploratory in the context of the limitations of this study. Further prospective evidence will highlight the efficacy and scope of colchicine in patients with AM.
SN  - 2297-055X
ER  -